Imugene Historical Income Statement

IMU Stock

0.04 0 5.26%

Historical analysis of Imugene income statement accounts such as Other Operating Expenses of 148 M or Total Operating Expenses of 141.8 M can show how well Imugene performed in making a profits. Evaluating Imugene income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Imugene's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Imugene latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Imugene is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Imugene Income Statement Analysis

Imugene Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Imugene shareholders. The income statement also shows Imugene investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Imugene Income Statement Chart

At this time, Imugene's Interest Income is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 4.2 M in 2024, despite the fact that EBITDA is likely to grow to (140.6 M).

Other Operating Expenses Total Operating Expenses Total Revenue Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Imugene. It is also known as Imugene overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Total Revenue

Total revenue comprises all receipts Imugene generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most accounts from Imugene's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Imugene current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imugene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	203.4K	190.3K	3.3M	3.5M
Net Interest Income	71.9K	1.9M	4.0M	4.2M

Reconciled Depreciation Net Interest Income

Imugene income statement Correlations

	Depreciation And Amortization	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Total Revenue	Gross Profit	Selling General Administrative	Net Income From Continuing Ops	Research Development	Cost Of Revenue	Selling And Marketing Expenses	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.9	0.95	-0.95	-0.95	-0.94	0.95	-0.95	-0.66	-0.94	-0.42	0.84	-0.38	0.95	-0.94	0.95	0.96	0.32	0.91	0.89	0.91
Interest Expense	0.9		0.95	-0.94	-0.95	-0.95	0.95	-0.95	-0.72	-0.97	-0.14	0.69	-0.66	0.94	-0.97	0.94	0.92	0.3	0.97	0.96	1.0
Other Operating Expenses	0.95	0.95		-1.0	-1.0	-1.0	1.0	-1.0	-0.74	-0.99	-0.43	0.88	-0.4	1.0	-0.99	1.0	0.99	0.33	0.97	0.96	0.96
Operating Income	-0.95	-0.94	-1.0		1.0	1.0	-1.0	1.0	0.74	0.99	0.45	-0.89	0.38	-1.0	0.99	-1.0	-0.99	-0.35	-0.96	-0.96	-0.95
Ebit	-0.95	-0.95	-1.0	1.0		1.0	-1.0	1.0	0.74	1.0	0.41	-0.87	0.42	-0.99	1.0	-1.0	-0.99	-0.34	-0.97	-0.96	-0.96
Ebitda	-0.94	-0.95	-1.0	1.0	1.0		-1.0	1.0	0.75	1.0	0.41	-0.87	0.42	-0.99	1.0	-1.0	-0.98	-0.34	-0.97	-0.96	-0.96
Total Operating Expenses	0.95	0.95	1.0	-1.0	-1.0	-1.0		-1.0	-0.74	-0.99	-0.43	0.88	-0.4	1.0	-0.99	1.0	0.99	0.33	0.97	0.96	0.96
Income Before Tax	-0.95	-0.95	-1.0	1.0	1.0	1.0	-1.0		0.75	1.0	0.41	-0.87	0.42	-0.99	1.0	-1.0	-0.99	-0.34	-0.97	-0.96	-0.96
Total Other Income Expense Net	-0.66	-0.72	-0.74	0.74	0.74	0.75	-0.74	0.75		0.75	0.26	-0.64	0.31	-0.69	0.74	-0.76	-0.68	-0.22	-0.66	-0.65	-0.73
Net Income	-0.94	-0.97	-0.99	0.99	1.0	1.0	-0.99	1.0	0.75		0.34	-0.83	0.49	-0.99	1.0	-0.99	-0.98	-0.33	-0.97	-0.97	-0.98
Income Tax Expense	-0.42	-0.14	-0.43	0.45	0.41	0.41	-0.43	0.41	0.26	0.34		-0.8	-0.64	-0.45	0.34	-0.45	-0.48	-0.32	-0.28	-0.28	-0.16
Total Revenue	0.84	0.69	0.88	-0.89	-0.87	-0.87	0.88	-0.87	-0.64	-0.83	-0.8		0.09	0.88	-0.82	0.89	0.9	0.34	0.77	0.77	0.71
Gross Profit	-0.38	-0.66	-0.4	0.38	0.42	0.42	-0.4	0.42	0.31	0.49	-0.64	0.09		-0.38	0.49	-0.38	-0.35	-0.04	-0.52	-0.51	-0.64
Selling General Administrative	0.95	0.94	1.0	-1.0	-0.99	-0.99	1.0	-0.99	-0.69	-0.99	-0.45	0.88	-0.38		-0.99	0.99	0.99	0.32	0.97	0.97	0.95
Net Income From Continuing Ops	-0.94	-0.97	-0.99	0.99	1.0	1.0	-0.99	1.0	0.74	1.0	0.34	-0.82	0.49	-0.99		-0.99	-0.98	-0.34	-0.98	-0.97	-0.98
Research Development	0.95	0.94	1.0	-1.0	-1.0	-1.0	1.0	-1.0	-0.76	-0.99	-0.45	0.89	-0.38	0.99	-0.99		0.99	0.34	0.96	0.95	0.95
Cost Of Revenue	0.96	0.92	0.99	-0.99	-0.99	-0.98	0.99	-0.99	-0.68	-0.98	-0.48	0.9	-0.35	0.99	-0.98	0.99		0.31	0.94	0.92	0.93
Selling And Marketing Expenses	0.32	0.3	0.33	-0.35	-0.34	-0.34	0.33	-0.34	-0.22	-0.33	-0.32	0.34	-0.04	0.32	-0.34	0.34	0.31		0.35	0.37	0.29
Interest Income	0.91	0.97	0.97	-0.96	-0.97	-0.97	0.97	-0.97	-0.66	-0.97	-0.28	0.77	-0.52	0.97	-0.98	0.96	0.94	0.35		1.0	0.97
Net Interest Income	0.89	0.96	0.96	-0.96	-0.96	-0.96	0.96	-0.96	-0.65	-0.97	-0.28	0.77	-0.51	0.97	-0.97	0.95	0.92	0.37	1.0		0.96
Reconciled Depreciation	0.91	1.0	0.96	-0.95	-0.96	-0.96	0.96	-0.96	-0.73	-0.98	-0.16	0.71	-0.64	0.95	-0.98	0.95	0.93	0.29	0.97	0.96

Click cells to compare fundamentals

Imugene Account Relationship Matchups

Imugene income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	82.5K	2.0M	2.4M	2.2M	5.8M	6.1M
Interest Expense	5.0K	5.0K	13.6K	27.5K	478.4K	502.3K
Other Operating Expenses	14.9M	25.7M	50.7M	51.3M	140.9M	148.0M
Operating Income	(14.9M)	(25.7M)	(50.7M)	(51.3M)	(140.9M)	(133.9M)
Ebit	(14.6M)	(25.7M)	(50.5M)	(49.6M)	(153.8M)	(146.1M)
Ebitda	(14.6M)	(23.7M)	(48.1M)	(47.4M)	(148.0M)	(140.6M)
Total Operating Expenses	14.8M	23.7M	48.3M	49.1M	135.1M	141.8M
Income Before Tax	(14.6M)	(25.7M)	(50.5M)	(49.7M)	(154.3M)	(146.6M)
Total Other Income Expense Net	(3.9M)	7.2M	(12.8M)	1.6M	(13.4M)	(12.7M)
Net Income	(10.5M)	(18.5M)	(37.9M)	(37.9M)	(149.7M)	(142.2M)
Income Tax Expense	(4.1M)	(7.2M)	(12.6M)	(11.7M)	(4.6M)	(4.4M)
Total Revenue	4.1M	7.2M	13.0M	11.8M	13.5M	14.2M
Gross Profit	4.1M	5.3M	10.6M	9.6M	(5.8M)	(5.5M)
Selling General Administrative	5.5M	10.3M	14.1M	20.4M	45.0M	47.3M
Net Income From Continuing Ops	(10.5M)	(18.5M)	(37.9M)	(39.2M)	(149.7M)	(142.2M)
Research Development	9.4M	15.4M	36.6M	30.9M	86.9M	91.2M
Cost Of Revenue	82.5K	2.0M	2.4M	2.2M	5.8M	6.1M
Net Income Applicable To Common Shares	(10.5M)	(18.5M)	(37.9M)	(37.9M)	(34.1M)	(32.4M)
Selling And Marketing Expenses	82.5K	154.8K	334.9K	506.5K	582.5K	305.7K
Interest Income	297.2K	126.6K	192.2K	1.9M	4.5M	4.7M
Net Interest Income	297.2K	10.5K	71.9K	1.9M	4.0M	4.2M
Reconciled Depreciation	82.5K	104.2K	203.4K	190.3K	3.3M	3.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Imugene Stock Analysis

When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC